Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Operations

v3.23.1
Consolidated Statements of Operations - USD ($)
shares in Thousands, $ in Thousands
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Income Statement [Abstract]    
Revenue, net $ 31,838 $ 33,117
Cost of revenue 13,607 14,314
Gross profit 18,231 18,803
Operating expenses:    
Sales and marketing 9,125 9,177
Research and development 703 1,493
General and administrative 10,973 10,705
Transition expense 897
Loss on DiamiR transaction 13
Acquisition related amortization expense 1,270 3,192
Change in fair value of contingent consideration (223) (338)
Total operating expenses 21,848 25,139
Operating loss from continuing operations (3,617) (6,336)
Interest accretion expense (158) (496)
Related party interest (424)
Note payable interest (850) (120)
Other expense, net (1,211) (366)
Loss from continuing operations before tax (5,836) (7,742)
Provision (benefit) for income taxes 29 (705)
Loss from continuing operations (5,865) (7,037)
Loss from discontinued operations, net of tax (16,093) (7,906)
Net loss $ (21,958) $ (14,943)
Basic and diluted loss per share of common stock:    
From continuing operations $ (1.38) $ (1.70)
From discontinued operations (3.80) (1.91)
Net loss per basic and diluted share of common stock $ (5.18) $ (3.61)
Weighted average number of common shares and common share equivalents outstanding:    
Basic 4,238 4,135
Diluted 4,238 4,135